Clinical trial NCT03266939: Rebalancing the Serotonergic System in Cocaine Dependence
Official title: Rebalancing the Serotonergic System in Cocaine Dependence
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Cocaine Dependence
Lead sponsor: Mclean Hospital
Sponsor class: OTHER
First posted: 2017-08-30
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: In the United States, 1.5 million people abuse cocaine leading to a host of negative health and economic consequences, yet no FDA approved treatment exists. To develop effective treatments, the following must be considered: 1) do potential medications ameliorate brain disruptions associated with cocaine use? 2) are multiple, targeted treatments necessary? To meet these goals, innovative multi-modal neuroimaging will be used to determine whether rebalancing the serotonergic (5-HT) system reduces cocaine cue reactivity, impulsivity, and normalizes related neurochemistry and brain connectivity.


Eligibility criteria: Inclusion Criteria:

* - Participants will be male and female volunteers between the ages of 18-55
* Participants will report having used cocaine on at least four occasions within the month prior to screening; the urine sample obtained during the screening visit must be positive for the cocaine metabolite benzoylecgonine (\>300 ng/ml). They can meet DSM-IV criteria for cocaine abuse and dependence.
* Participants cannot meet DSM-IV criteria for current psychotic disorders (e.g., bipolar disorder, schizophrenia, schizoaffective disorder)
* Participants cannot meet DSM-IV criteria for a current major depressive episode
* Participants cannot meet DSM-IV criteria for current drug dependence (except nicotine, cocaine, and marihuana)
* Participants must test negative for alcohol use on the day of the scan.
* Participants can report current abuse of marihuana and tobacco. Participants cannot have used marihuana within twelve hours of their study visits.
* Participants cannot be regular opiate users including prescription opiate analgesics
* Participants cannot have a history of major head trauma resulting in cognitive impairment, seizure, or other neurological disorders.
* Participants cannot have any conditions that are contraindicated for MRI (see next section)
* Participants cannot be pregnant (pregnancy test will be performed before each scanning session)
* Participants must be able to read screening materials including consent form and give informed consent
* Participants cannot be taking any medications with a 5-HT mechanism including serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and St. John's Wort and tryptophan.
* Participants cannot be currently taking any medications that might affect the central nervous system including prescription analgesics, anxiolytics, antipsychotics, and antidepressants. A complete review of medications will be evaluated by study staff.
* Cannot have any history of a medical condition that might affect the central nervous system at the time of scanning including: Abnormal structural MRI, or a history of head trauma or injury causing loss of consciousness lasting longer than 3 minutes or associated with skull fracture or intracranial bleeding or who had irremovable magnetically active objects on or within their body, or history of epilepsy.

Exclusion Criteria:

* - Weight greater than 350 pounds (cannot easily fit inside the magnet bore)
* Cardiac pacemakers
* Aneurysm clips and other vascular stents, filters, clips or other devices
* Prosthetic heart valves
* Other prostheses
* Neuro-stimulator devices
* Implanted infusion pumps
* Cochlear implants
* Ocular implants or known metal fragments in eyes
* Exposure to shrapnel or metal filings (sheet metal workers, welders, and others)
* Other metallic surgical hardware in vital areas
* History of major head trauma resulting in cognitive impairment
* Certain tattoos (e.g. older dye with metallic pigment)
* Certain medication patches (if they cannot be removed)
* Metal containing IUDs
* Claustrophobia
* Pregnancy
* Metallic implants except fillings and crowns
* Tattoos containing metallic ink on the neck, shoulders, upper arm, and head (these could become heated during scanning, potentially causing burns
* Medication patches that cannot be removed during scanning
* Claustrophobia

Primary outcomes:
measure: Influence of lorcaserin on fMRI measured brain-reactivity to drug cues.
timeFrame: fMRI measures will be gathered on scanning visits 1 and 2 (approx 1 week apart)
Secondary outcomes:
Other outcomes:
Locations:
city: Belmont
country: United States
facility: McLean Hospital
state: Massachusetts
Study officials:
affiliation: Mclean Hospital
name: Amy Janes, PhD
role: PRINCIPAL_INVESTIGATOR
References: